What is Cingulate?
Cingulate operates at the intersection of pharmaceutical engineering and patient-centric care. Founded in 2012 and headquartered in Kansas City, the company specializes in the development of next-generation therapeutics designed to mitigate the challenges of burdensome daily dosing schedules. Its core asset, the Precision Timed Release (PTR) platform, is engineered to optimize drug delivery, thereby enhancing treatment outcomes for patients with frequently diagnosed conditions. By focusing on the intersection of pharmacokinetics and patient compliance, Cingulate occupies a unique niche in the biopharmaceutical landscape, aiming to transform standard-of-care protocols through technological innovation.
How much funding has Cingulate raised?
Cingulate has raised a total of $26.3M across 6 funding rounds:
Private Equity
$6.8M
Private Equity
$7.5M
Debt
$150K
Debt
$237K
Share Placement
$5M
Debt
$6.6M
Private Equity (2013): $6.8M, investors not publicly disclosed
Private Equity (2018): $7.5M led by Werth Family Investment Associates
Debt (2020): $150K supported by PPP
Debt (2021): $237K featuring PPP
Share Placement (2024): $5M, investors not publicly disclosed
Debt (2025): $6.6M, investors not publicly disclosed
Key Investors in Cingulate
Werth Family Investment Associates
A private investment firm focused on long-term capital appreciation and strategic support for growth-oriented enterprises.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round, providing essential capital to drive clinical development milestones.
What's next for Cingulate?
With the recent influx of capital, Cingulate is poised to transition into a more mature phase of its clinical lifecycle. The strategic focus will likely center on the advancement of its lead candidates through late-stage clinical trials and the potential commercialization of its PTR-enabled products. As the company navigates the complexities of regulatory approval and market entry, the emphasis will remain on demonstrating the clinical superiority of its delivery platform. Future growth will be contingent upon the successful execution of its R&D roadmap and the ability to scale manufacturing capabilities to meet anticipated demand in the competitive pharmaceutical sector.
See full Cingulate company page
